{"id":"erenumab-dose-1","safety":{"commonSideEffects":[{"rate":"26","effect":"Injection site reactions"},{"rate":"8","effect":"Nasopharyngitis"},{"rate":"7","effect":"Upper respiratory tract infection"},{"rate":"5","effect":"Sinusitis"},{"rate":"4","effect":"Constipation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By binding to and neutralizing CGRP, erenumab prevents its interaction with CGRP receptors on sensory neurons, thereby reducing migraine frequency and severity. This mechanism addresses a key biological pathway implicated in both episodic and chronic migraine.","oneSentence":"Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:27.506Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Episodic migraine prevention"},{"name":"Chronic migraine prevention"}]},"trialDetails":[{"nctId":"NCT04271202","phase":"PHASE4","title":"Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2020-07-29","conditions":"Chronic Migraine","enrollment":64},{"nctId":"NCT03832998","phase":"PHASE3","title":"Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-09-05","conditions":"Migraine","enrollment":284},{"nctId":"NCT05334927","phase":"","title":"China HeadAche DIsorders RegiStry","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2022-08-29","conditions":"Headache Disorders, Primary, Migraine, New Daily Persistent Headache","enrollment":10000},{"nctId":"NCT03836040","phase":"PHASE3","title":"Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-07-19","conditions":"Migraine","enrollment":457},{"nctId":"NCT05684692","phase":"PHASE2","title":"Screening Trial for Pain Relief in Schwannomatosis (STARFISH)","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-08-31","conditions":"Schwannomatosis, Schwannomas, Pain, Chronic","enrollment":40},{"nctId":"NCT04417361","phase":"PHASE2","title":"Galcanezumab for Vestibular Migraine","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-09-18","conditions":"Vestibular Migraine","enrollment":40},{"nctId":"NCT01952574","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-08-06","conditions":"Migraine","enrollment":483},{"nctId":"NCT02630459","phase":"PHASE2","title":"A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-01-06","conditions":"Migraine","enrollment":475},{"nctId":"NCT02456740","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-07-17","conditions":"Migraine","enrollment":955},{"nctId":"NCT04334408","phase":"PHASE2","title":"Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2021-12","conditions":"Cadasil, Migraine","enrollment":""},{"nctId":"NCT04179474","phase":"PHASE1","title":"Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2019-09-26","conditions":"Migraine","enrollment":40},{"nctId":"NCT04114630","phase":"PHASE3","title":"Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2019-10-30","conditions":"Migraine","enrollment":""},{"nctId":"NCT02542605","phase":"PHASE1","title":"To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-11","conditions":"Migraine","enrollment":35},{"nctId":"NCT02741310","phase":"PHASE1","title":"Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-22","conditions":"Healthy Subjects","enrollment":34},{"nctId":"NCT01723514","phase":"PHASE1","title":"Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-14","conditions":"Migraine","enrollment":48},{"nctId":"NCT01688739","phase":"PHASE1","title":"Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-13","conditions":"Migraine","enrollment":61},{"nctId":"NCT02792517","phase":"PHASE1","title":"Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-12","conditions":"Headache, Migraine","enrollment":41},{"nctId":"NCT02575833","phase":"PHASE2","title":"Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-11-23","conditions":"Stable Angina","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 334","Aimovig®","AMG334"],"phase":"phase_3","status":"active","brandName":"Erenumab Dose 1","genericName":"Erenumab Dose 1","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Episodic migraine prevention, Chronic migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}